Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide
NCT07537699 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25
Last updated 2026-04-17
Summary
The goal of this clinical trial is to learn if auricular point stimulation plus dexamethasone works to effectively prevent or suppress nausea and vomiting caused by docetaxel combined with cyclophosphamide in breast cancer adjuvant chemotherapy. It will also learn about the safety and influence on gastrointestinal function of auricular point stimulation plus dexamethasone.
The main questions it aims to answer are:
Can auricular point stimulation plus dexamethasone effectively prevent or suppress nausea and vomiting induced by the docetaxel plus cyclophosphamide regimen? Can auricular point stimulation plus dexamethasone effectively reduce the incidence of appetite loss, weakened or disordered gastrointestinal function, and other uncomfortable conditions caused by excessive use of antiemetic drugs?
Participants will:
Receive auricular acupressure with bean seeds on specific points of one ear, plus intravenous injection of dexamethasone as a preventive antiemetic treatment within half an hour before chemotherapy. Starting from the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5), provide regular stimulation at the acupressure points daily by themselves according to the protocol provided in this trial. Record their nausea and vomiting status, appetite, and gastrointestinal function-related symptomatic indicators from Day 1 to Day 5. Oral antiemetics are also prepared. If nausea and vomiting are significant or the patient feels the need, they may be temporarily administered as an adjunct.
Conditions
- Nausea and Vomiting Caused by Chemotherapy
Interventions
- OTHER
-
Auricular point stimulation plus dexamethasone
On the day of chemotherapy (Day 1): Within half an hour before chemotherapy, administer auricular acupressure on one ear (stimulating the stomach, cardia, and brainstem acupoints for 5 minutes each) along with an intravenous push of 5 mg dexamethasone. From the day of chemotherapy (Day 1) to the following five days (Day 1-Day 5): Stimulate each acupoint once in the morning, noon, and evening, for 5 minutes each time. If nausea or vomiting occurs, immediately apply additional stimulation for 5 minutes as a temporary measure. Oral antiemetics should be prepared and may be used temporarily if nausea and vomiting are significant and the patient feels the need.
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Principal Investigators
-
Juan Wang · Second Affiliated Hospital, School of Medicine, Zhejiang University
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-11-25
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
Countries
- China
Study Locations
More Related Trials
-
Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer
NCT06200168 ·Status: RECRUITING ·Phase: PHASE3
-
Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients
NCT02403037 ·Status: COMPLETED ·Phase: NA
-
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
NCT03668639 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
NCT00016380 ·Status: COMPLETED ·Phase: PHASE3
-
A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients
NCT07254416 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy
NCT04430361 ·Status: UNKNOWN ·Phase: PHASE2
-
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
NCT01913990 ·Status: UNKNOWN ·Phase: PHASE4
-
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
NCT01370408 ·Status: COMPLETED ·Phase: PHASE2
-
Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer
NCT02550795 ·Status: COMPLETED ·Phase: NA
-
Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting
NCT02933099 ·Status: UNKNOWN ·Phase: PHASE3
-
Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy
NCT02550119 ·Status: TERMINATED ·Phase: NA
-
NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer
NCT03862144 ·Status: COMPLETED ·Phase: PHASE2
-
Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting
NCT05143554 ·Status: TERMINATED ·Phase: NA
-
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
NCT00869973 ·Status: TERMINATED ·Phase: PHASE3
-
Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT06314906 ·Status: RECRUITING ·Phase: PHASE3
-
Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin
NCT04201769 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea
NCT04937309 ·Status: RECRUITING ·Phase: NA
-
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
NCT00952341 ·Status: COMPLETED ·Phase: PHASE3
-
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
NCT00293384 ·Status: COMPLETED ·Phase: NA
-
Aprepitant in the Prevention of Cisplatin-induced Delayed Emesis
NCT00869310 ·Status: TERMINATED ·Phase: PHASE3
-
Continuous Infusion of First-Generation 5-HT3 Receptor Antagonists in Combination With Dexamethasone
NCT05872893 ·Status: COMPLETED ·Phase: PHASE3
-
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
NCT00152867 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of Dexamethasone Alone vs in Combination With Pericardium 6 (P6) Electrical Stimulation or Granisetron in the Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Breast Cancer Surgery
NCT05408676 ·Status: COMPLETED ·Phase: NA
-
Nausea or Vomiting in Patients Who Are Receiving Chemotherapy for Breast Cancer or Lung Cancer
NCT00416689 ·Status: COMPLETED
-
Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer
NCT05564286 ·Status: COMPLETED ·Phase: PHASE3